STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

United Therapeutics files Form 144 for minor 645-share insider sale

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

United Therapeutics Corp (UTHR) – Form 144 filing: An insider has notified the SEC of a planned sale of 645 common shares through Morgan Stanley Smith Barney on or about 24 June 2025. The shares were originally received as restricted stock on 13 July 2024 directly from the issuer. The proposed transaction has an aggregate market value of $187,045.23, representing roughly 0.001 % of the company’s 45,106,623 shares outstanding. No prior sales were reported in the past three months. Because the volume is extremely small relative to the float and there are no accompanying disclosures of adverse information, the filing appears routine and is unlikely to affect United Therapeutics’ capital structure or trading liquidity.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Minor Form 144: 645-share insider sale (~$187k) is immaterial to UTHR’s float; transaction should have negligible market impact.

The filing signals a future disposition of 645 shares—about 0.001 % of shares outstanding—under Rule 144. Such a small sale, valued at under $0.2 million versus a multi-billion-dollar market cap, does not alter supply–demand dynamics or suggest negative fundamentals. The absence of other recent insider sales reduces concern over broader sentiment shifts. Overall, this is a routine administrative disclosure rather than a catalyst.

TL;DR: Filing is standard compliance; volume trivial, no strategic implications, thus governance risk remains unchanged.

Rule 144 requires advance notice for certain insider resales, promoting transparency. The filer affirms no undisclosed material adverse information. Given the limited volume and restricted-stock origin, it likely reflects personal liquidity rather than strategic divestment. No aggregation with other insiders is reported. Therefore, from a governance standpoint, red-flag risk is minimal.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING